RATIONALE: A reliable asthma diagnosis is difficult in wheezing preschool children. OBJECTIVES: To assess whether exhaled biomarkers, expression of inflammation genes, and early lung function measurements can improve a reliable asthma prediction in preschool wheezing children. METHODS: Two hundred two preschool recurrent wheezers (aged 2-4 yr) were prospectively followed up until 6 years of age. At 6 years of age, a diagnosis (asthma or transient wheeze) was based on symptoms, lung function, and asthma medication use. The added predictive value (area under the receiver operating characteristic curve [AUC]) of biomarkers to clinical information (assessed with the Asthma Predictive Index [API]) assessed at preschool age in diagnosing asthma at 6 years of age was determined with a validation set. Biomarkers in exhaled breath condensate, exhaled volatile organic compounds (VOCs), gene expression, and airway resistance were measured. MEASUREMENTS AND MAIN RESULTS: At 6 years of age, 198 children were diagnosed (76 with asthma, 122 with transient wheeze). Information on exhaled VOCs significantly improved asthma prediction (AUC, 89% [increase of 28%]; positive predictive value [PPV]/negative predictive value [NPV], 82/83%), which persisted in the validation set. Information on gene expression of toll-like receptor 4, catalase, and tumor necrosis factor-α significantly improved asthma prediction (AUC, 75% [increase of 17%]; PPV/NPV, 76/73%). This could not be confirmed after validation. Biomarkers in exhaled breath condensate and airway resistance (pre- and post- bronchodilator) did not improve an asthma prediction. The combined model with VOCs, gene expression, and API had an AUC of 95% (PPV/NPV, 90/89%). CONCLUSIONS: Adding information on exhaled VOCs and possibly expression of inflammation genes to the API significantly improves an accurate asthma diagnosis in preschool children. Clinical trial registered with www.clinicaltrial.gov (NCT 00422747).
RATIONALE: A reliable asthma diagnosis is difficult in wheezing preschool children. OBJECTIVES: To assess whether exhaled biomarkers, expression of inflammation genes, and early lung function measurements can improve a reliable asthma prediction in preschool wheezingchildren. METHODS: Two hundred two preschool recurrent wheezers (aged 2-4 yr) were prospectively followed up until 6 years of age. At 6 years of age, a diagnosis (asthma or transient wheeze) was based on symptoms, lung function, and asthma medication use. The added predictive value (area under the receiver operating characteristic curve [AUC]) of biomarkers to clinical information (assessed with the Asthma Predictive Index [API]) assessed at preschool age in diagnosing asthma at 6 years of age was determined with a validation set. Biomarkers in exhaled breath condensate, exhaled volatile organic compounds (VOCs), gene expression, and airway resistance were measured. MEASUREMENTS AND MAIN RESULTS: At 6 years of age, 198 children were diagnosed (76 with asthma, 122 with transient wheeze). Information on exhaled VOCs significantly improved asthma prediction (AUC, 89% [increase of 28%]; positive predictive value [PPV]/negative predictive value [NPV], 82/83%), which persisted in the validation set. Information on gene expression of toll-like receptor 4, catalase, and tumor necrosis factor-α significantly improved asthma prediction (AUC, 75% [increase of 17%]; PPV/NPV, 76/73%). This could not be confirmed after validation. Biomarkers in exhaled breath condensate and airway resistance (pre- and post- bronchodilator) did not improve an asthma prediction. The combined model with VOCs, gene expression, and API had an AUC of 95% (PPV/NPV, 90/89%). CONCLUSIONS: Adding information on exhaled VOCs and possibly expression of inflammation genes to the API significantly improves an accurate asthma diagnosis in preschool children. Clinical trial registered with www.clinicaltrial.gov (NCT 00422747).
Authors: Jocelyn M Biagini Myers; Eric Schauberger; Hua He; Lisa J Martin; John Kroner; Gregory M Hill; Patrick H Ryan; Grace K LeMasters; David I Bernstein; James E Lockey; S Hasan Arshad; Ramesh Kurukulaaratchy; Gurjit K Khurana Hershey Journal: J Allergy Clin Immunol Date: 2018-12-13 Impact factor: 10.793
Authors: Harsheen Kaur; Sunghwan Sohn; Chung-Il Wi; Euijung Ryu; Miguel A Park; Kay Bachman; Hirohito Kita; Ivana Croghan; Jose A Castro-Rodriguez; Gretchen A Voge; Hongfang Liu; Young J Juhn Journal: BMC Pulm Med Date: 2018-02-13 Impact factor: 3.317
Authors: Rosa A Sola Martínez; José M Pastor Hernández; Óscar Yanes Torrado; Manuel Cánovas Díaz; Teresa de Diego Puente; María Vinaixa Crevillent Journal: Pediatr Res Date: 2020-09-12 Impact factor: 3.756
Authors: Rosa A Sola-Martínez; Gema Lozano-Terol; Julia Gallego-Jara; Eva Morales; Esther Cantero-Cano; Manuel Sanchez-Solis; Luis García-Marcos; Pedro Jiménez-Guerrero; José A Noguera-Velasco; Manuel Cánovas Díaz; Teresa de Diego Puente Journal: Sci Rep Date: 2021-07-05 Impact factor: 4.379
Authors: Gang Luo; Flory L Nkoy; Bryan L Stone; Darell Schmick; Michael D Johnson Journal: BMC Med Inform Decis Mak Date: 2015-11-28 Impact factor: 2.796